ArticleBiomarker research2026
Multidimensional 5-hydroxymethylcytosine features in cell-free DNA enable the detection, staging and subtyping of pancreatic ductal adenocarcinoma.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignant cancer with limited biomarkers for early detection and disease stratification. Here, we investigated whether multidimensional 5-hydroxymethylcytosine (5hmC) features in plasma cell-free DNA (cfDNA) could support the noninvasive detection, staging, and subtyping of PDAC. We performed a genome-wide cfDNA 5hmC analysis in 274 individuals, including 204 patients with PDAC and 70 non-PDAC controls, and extracted seven categories of features covering both coverage-based and fragmentomic signals. PDAC was characterized by widespread and structured 5hmC alterations across multiple genomic and fragment-level feature classes, and these signals reflect widespread multitissue perturbation rather than pancreatic tissue contribution alone. Stage-related analyses revealed a progressive shift from early developmental and metabolic programs toward later immune- and stroma-associated programs. Pathological subtype analysis further suggested progression-associated ordering defined by lymph node metastasis and vascular invasion, with partially distinct molecular features associated with different invasive patterns. Motivated by these findings, we developed a two-level machine learning framework that integrates multiple 5hmC feature types. The final stacked model achieved strong performance for PDAC detection (ROC-AUC = 0.952), while the staging model showed moderate discrimination (macro-AUC = 0.721), and the subtyping model demonstrated good performance (micro-AUC = 0.831; macro-AUC = 0.818). These findings suggest that multidimensional cfDNA 5hmC profiling provides a promising noninvasive framework for PDAC detection, stage assessment, and pathological subtyping.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.